MedTrace Logo

HMB and Exercise-induced Muscle Damage

NCT04549610 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-23

No results posted yet for this study

Summary

The study aims at assessing the influence of β-hydroxy-β-methylbutyrate (HMB) supplementation (4.0 g/day) supplemented for 7 days in a group of speed-strength trained individuals on lower-body strength performance, selected muscle histological, molecular and blood markers of muscle recovery in response to resistance exercise-induced muscle damage.

Conditions

  • Supplementation
  • Sport
  • Sports Nutrition
  • Muscle Damage
  • Recovery

Interventions

DIETARY_SUPPLEMENT

HMB supplementation

Group taking oral HMB supplementation in a blinded capsule form.

DIETARY_SUPPLEMENT

Placebo treatment

Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.

Sponsors & Collaborators

  • Escola de Educação Física e Esporte da Universidade de São Paulo (Brazil) - Parallel sponsor of the research

    collaborator UNKNOWN

  • National Science Centre, Poland

    collaborator OTHER_GOV

  • Poznan University of Physical Education

    lead OTHER

Principal Investigators

  • Guilherme G Artioli, Prof., PhD · Applied Physiology & Nutrition Research Group, University of Sao Paulo. Sao Paulo, SP. Brazil.

  • Krzysztof Durkalec-Michalski, Dr hab., PhD · Department of Sports Dietetics, Poznan University of Physical Education, Poznań, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2024-12-01
Completion
2025-01-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549610 on ClinicalTrials.gov